Zaleplon and triazolam: drug discrimination, plasma levels, and self-administration in baboons
Zaleplon is a chemically novel hypnotic that preferentially binds α 1-subunit containing subtypes of the αβγ configuration of the γ-aminobutyric acid (GABA) A receptor. Zaleplon and the non-subtype-selective hypnotic triazolam occasioned 100% drug-appropriate responding in baboons trained to discrim...
Gespeichert in:
| Veröffentlicht in: | Drug and alcohol dependence 2000-12, Vol.61 (1), p.55-68 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 68 |
|---|---|
| container_issue | 1 |
| container_start_page | 55 |
| container_title | Drug and alcohol dependence |
| container_volume | 61 |
| creator | Ator, N.A |
| description | Zaleplon is a chemically novel hypnotic that preferentially binds α
1-subunit containing subtypes of the αβγ configuration of the γ-aminobutyric acid (GABA)
A receptor. Zaleplon and the non-subtype-selective hypnotic triazolam occasioned 100% drug-appropriate responding in baboons trained to discriminate lorazepam or pentobarbital from vehicle. Flumazenil shifted the zaleplon generalization gradient at least five-fold to the right. A plasma elimination half-life of 6–8 h for oral 10 mg/kg zaleplon and 0.32 mg/kg triazolam was paralleled by discriminative control for 7 h. Zaleplon maintained self-injection greater than vehicle, as did comparison doses of the similarly selective hypnotic zolpidem and triazolam. Concurrent food-maintained responding increased during self-injection of all three drugs. Preferential binding at this α
1-containing GABA
A subtype did not diminish the benzodiazepine (Bzs)-like behavioral effects of zaleplon. |
| doi_str_mv | 10.1016/S0376-8716(00)00123-X |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72390507</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S037687160000123X</els_id><sourcerecordid>72390507</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-45a0455b28c6f95bcb3267a61767afae648ec99af4ebebdd4dba548bc8aecee93</originalsourceid><addsrcrecordid>eNqFkU9rFDEYh4NY7Fr7EZQ5iCh09M1OJjPjpZRSW6HgQQulh4Y3yTsSySTbZLagn77p7lK9mUNyeX7vnyeMvebwkQOXn75D08m677h8D_ABgC-b-voZW_C-G2oAIZ-zxROyz17m_AvKkQO8YPucgxS8Fwt2e4OeVj6GCoOt5uTwT_Q4fa5sWv-srMsmuckFnF0MR9XKY56w8nRPPh9tIpn8WKMtjMtz2nCVC5VGHWPIr9jeiD7T4e49YFdfzn6cXtSX386_np5c1qYZYK5FiyDaVi97I8eh1UY3S9mh5F25RyQpejLDgKMgTdpaYTW2otemRzJEQ3PA3m3rrlK8W1Oe1VRGJ-8xUFxn1S1Lnxa6ArZb0KSYc6JRrcqCmH4rDupRrNqIVY_WFIDaiFXXJfdm12CtJ7J_UzuTBXi7AzAb9GPCYFz-p3r5kwYKdrzFikC6d5RUNo6CIesSmVnZ6P4zyQM-ipcS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72390507</pqid></control><display><type>article</type><title>Zaleplon and triazolam: drug discrimination, plasma levels, and self-administration in baboons</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Ator, N.A</creator><creatorcontrib>Ator, N.A</creatorcontrib><description>Zaleplon is a chemically novel hypnotic that preferentially binds α
1-subunit containing subtypes of the αβγ configuration of the γ-aminobutyric acid (GABA)
A receptor. Zaleplon and the non-subtype-selective hypnotic triazolam occasioned 100% drug-appropriate responding in baboons trained to discriminate lorazepam or pentobarbital from vehicle. Flumazenil shifted the zaleplon generalization gradient at least five-fold to the right. A plasma elimination half-life of 6–8 h for oral 10 mg/kg zaleplon and 0.32 mg/kg triazolam was paralleled by discriminative control for 7 h. Zaleplon maintained self-injection greater than vehicle, as did comparison doses of the similarly selective hypnotic zolpidem and triazolam. Concurrent food-maintained responding increased during self-injection of all three drugs. Preferential binding at this α
1-containing GABA
A subtype did not diminish the benzodiazepine (Bzs)-like behavioral effects of zaleplon.</description><identifier>ISSN: 0376-8716</identifier><identifier>EISSN: 1879-0046</identifier><identifier>DOI: 10.1016/S0376-8716(00)00123-X</identifier><identifier>PMID: 11064184</identifier><identifier>CODEN: DADEDV</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Abuse potential ; Acetamides - administration & dosage ; Acetamides - blood ; Acetamides - pharmacology ; Animals ; Behavior, Animal - drug effects ; Biological and medical sciences ; CL 284,846 ; Discrimination Learning - drug effects ; Dose-Response Relationship, Drug ; Drug discrimination ; Feeding ; Flumazenil ; GABA Modulators - administration & dosage ; GABA Modulators - blood ; GABA Modulators - pharmacology ; Hypnotics and Sedatives - administration & dosage ; Hypnotics and Sedatives - blood ; Hypnotics and Sedatives - pharmacology ; Hypnotics. Sedatives ; Male ; Medical sciences ; Neuropharmacology ; Papio ; Pharmacokinetics ; Pharmacology. Drug treatments ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Pyrimidines - administration & dosage ; Pyrimidines - blood ; Pyrimidines - pharmacology ; Self Administration ; Triazolam ; Triazolam - administration & dosage ; Triazolam - blood ; Triazolam - pharmacology ; Zaleplon ; Zolpidem</subject><ispartof>Drug and alcohol dependence, 2000-12, Vol.61 (1), p.55-68</ispartof><rights>2000 Elsevier Science Ireland Ltd</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-45a0455b28c6f95bcb3267a61767afae648ec99af4ebebdd4dba548bc8aecee93</citedby><cites>FETCH-LOGICAL-c390t-45a0455b28c6f95bcb3267a61767afae648ec99af4ebebdd4dba548bc8aecee93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0376-8716(00)00123-X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27911,27912,45982</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1000430$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11064184$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ator, N.A</creatorcontrib><title>Zaleplon and triazolam: drug discrimination, plasma levels, and self-administration in baboons</title><title>Drug and alcohol dependence</title><addtitle>Drug Alcohol Depend</addtitle><description>Zaleplon is a chemically novel hypnotic that preferentially binds α
1-subunit containing subtypes of the αβγ configuration of the γ-aminobutyric acid (GABA)
A receptor. Zaleplon and the non-subtype-selective hypnotic triazolam occasioned 100% drug-appropriate responding in baboons trained to discriminate lorazepam or pentobarbital from vehicle. Flumazenil shifted the zaleplon generalization gradient at least five-fold to the right. A plasma elimination half-life of 6–8 h for oral 10 mg/kg zaleplon and 0.32 mg/kg triazolam was paralleled by discriminative control for 7 h. Zaleplon maintained self-injection greater than vehicle, as did comparison doses of the similarly selective hypnotic zolpidem and triazolam. Concurrent food-maintained responding increased during self-injection of all three drugs. Preferential binding at this α
1-containing GABA
A subtype did not diminish the benzodiazepine (Bzs)-like behavioral effects of zaleplon.</description><subject>Abuse potential</subject><subject>Acetamides - administration & dosage</subject><subject>Acetamides - blood</subject><subject>Acetamides - pharmacology</subject><subject>Animals</subject><subject>Behavior, Animal - drug effects</subject><subject>Biological and medical sciences</subject><subject>CL 284,846</subject><subject>Discrimination Learning - drug effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug discrimination</subject><subject>Feeding</subject><subject>Flumazenil</subject><subject>GABA Modulators - administration & dosage</subject><subject>GABA Modulators - blood</subject><subject>GABA Modulators - pharmacology</subject><subject>Hypnotics and Sedatives - administration & dosage</subject><subject>Hypnotics and Sedatives - blood</subject><subject>Hypnotics and Sedatives - pharmacology</subject><subject>Hypnotics. Sedatives</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Papio</subject><subject>Pharmacokinetics</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Pyrimidines - administration & dosage</subject><subject>Pyrimidines - blood</subject><subject>Pyrimidines - pharmacology</subject><subject>Self Administration</subject><subject>Triazolam</subject><subject>Triazolam - administration & dosage</subject><subject>Triazolam - blood</subject><subject>Triazolam - pharmacology</subject><subject>Zaleplon</subject><subject>Zolpidem</subject><issn>0376-8716</issn><issn>1879-0046</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9rFDEYh4NY7Fr7EZQ5iCh09M1OJjPjpZRSW6HgQQulh4Y3yTsSySTbZLagn77p7lK9mUNyeX7vnyeMvebwkQOXn75D08m677h8D_ABgC-b-voZW_C-G2oAIZ-zxROyz17m_AvKkQO8YPucgxS8Fwt2e4OeVj6GCoOt5uTwT_Q4fa5sWv-srMsmuckFnF0MR9XKY56w8nRPPh9tIpn8WKMtjMtz2nCVC5VGHWPIr9jeiD7T4e49YFdfzn6cXtSX386_np5c1qYZYK5FiyDaVi97I8eh1UY3S9mh5F25RyQpejLDgKMgTdpaYTW2otemRzJEQ3PA3m3rrlK8W1Oe1VRGJ-8xUFxn1S1Lnxa6ArZb0KSYc6JRrcqCmH4rDupRrNqIVY_WFIDaiFXXJfdm12CtJ7J_UzuTBXi7AzAb9GPCYFz-p3r5kwYKdrzFikC6d5RUNo6CIesSmVnZ6P4zyQM-ipcS</recordid><startdate>20001222</startdate><enddate>20001222</enddate><creator>Ator, N.A</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20001222</creationdate><title>Zaleplon and triazolam: drug discrimination, plasma levels, and self-administration in baboons</title><author>Ator, N.A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-45a0455b28c6f95bcb3267a61767afae648ec99af4ebebdd4dba548bc8aecee93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Abuse potential</topic><topic>Acetamides - administration & dosage</topic><topic>Acetamides - blood</topic><topic>Acetamides - pharmacology</topic><topic>Animals</topic><topic>Behavior, Animal - drug effects</topic><topic>Biological and medical sciences</topic><topic>CL 284,846</topic><topic>Discrimination Learning - drug effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug discrimination</topic><topic>Feeding</topic><topic>Flumazenil</topic><topic>GABA Modulators - administration & dosage</topic><topic>GABA Modulators - blood</topic><topic>GABA Modulators - pharmacology</topic><topic>Hypnotics and Sedatives - administration & dosage</topic><topic>Hypnotics and Sedatives - blood</topic><topic>Hypnotics and Sedatives - pharmacology</topic><topic>Hypnotics. Sedatives</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Papio</topic><topic>Pharmacokinetics</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Pyrimidines - administration & dosage</topic><topic>Pyrimidines - blood</topic><topic>Pyrimidines - pharmacology</topic><topic>Self Administration</topic><topic>Triazolam</topic><topic>Triazolam - administration & dosage</topic><topic>Triazolam - blood</topic><topic>Triazolam - pharmacology</topic><topic>Zaleplon</topic><topic>Zolpidem</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ator, N.A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drug and alcohol dependence</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ator, N.A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Zaleplon and triazolam: drug discrimination, plasma levels, and self-administration in baboons</atitle><jtitle>Drug and alcohol dependence</jtitle><addtitle>Drug Alcohol Depend</addtitle><date>2000-12-22</date><risdate>2000</risdate><volume>61</volume><issue>1</issue><spage>55</spage><epage>68</epage><pages>55-68</pages><issn>0376-8716</issn><eissn>1879-0046</eissn><coden>DADEDV</coden><abstract>Zaleplon is a chemically novel hypnotic that preferentially binds α
1-subunit containing subtypes of the αβγ configuration of the γ-aminobutyric acid (GABA)
A receptor. Zaleplon and the non-subtype-selective hypnotic triazolam occasioned 100% drug-appropriate responding in baboons trained to discriminate lorazepam or pentobarbital from vehicle. Flumazenil shifted the zaleplon generalization gradient at least five-fold to the right. A plasma elimination half-life of 6–8 h for oral 10 mg/kg zaleplon and 0.32 mg/kg triazolam was paralleled by discriminative control for 7 h. Zaleplon maintained self-injection greater than vehicle, as did comparison doses of the similarly selective hypnotic zolpidem and triazolam. Concurrent food-maintained responding increased during self-injection of all three drugs. Preferential binding at this α
1-containing GABA
A subtype did not diminish the benzodiazepine (Bzs)-like behavioral effects of zaleplon.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>11064184</pmid><doi>10.1016/S0376-8716(00)00123-X</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0376-8716 |
| ispartof | Drug and alcohol dependence, 2000-12, Vol.61 (1), p.55-68 |
| issn | 0376-8716 1879-0046 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72390507 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Abuse potential Acetamides - administration & dosage Acetamides - blood Acetamides - pharmacology Animals Behavior, Animal - drug effects Biological and medical sciences CL 284,846 Discrimination Learning - drug effects Dose-Response Relationship, Drug Drug discrimination Feeding Flumazenil GABA Modulators - administration & dosage GABA Modulators - blood GABA Modulators - pharmacology Hypnotics and Sedatives - administration & dosage Hypnotics and Sedatives - blood Hypnotics and Sedatives - pharmacology Hypnotics. Sedatives Male Medical sciences Neuropharmacology Papio Pharmacokinetics Pharmacology. Drug treatments Psychology. Psychoanalysis. Psychiatry Psychopharmacology Pyrimidines - administration & dosage Pyrimidines - blood Pyrimidines - pharmacology Self Administration Triazolam Triazolam - administration & dosage Triazolam - blood Triazolam - pharmacology Zaleplon Zolpidem |
| title | Zaleplon and triazolam: drug discrimination, plasma levels, and self-administration in baboons |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T02%3A06%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Zaleplon%20and%20triazolam:%20drug%20discrimination,%20plasma%20levels,%20and%20self-administration%20in%20baboons&rft.jtitle=Drug%20and%20alcohol%20dependence&rft.au=Ator,%20N.A&rft.date=2000-12-22&rft.volume=61&rft.issue=1&rft.spage=55&rft.epage=68&rft.pages=55-68&rft.issn=0376-8716&rft.eissn=1879-0046&rft.coden=DADEDV&rft_id=info:doi/10.1016/S0376-8716(00)00123-X&rft_dat=%3Cproquest_cross%3E72390507%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72390507&rft_id=info:pmid/11064184&rft_els_id=S037687160000123X&rfr_iscdi=true |